<code id='730DFA2468'></code><style id='730DFA2468'></style>
    • <acronym id='730DFA2468'></acronym>
      <center id='730DFA2468'><center id='730DFA2468'><tfoot id='730DFA2468'></tfoot></center><abbr id='730DFA2468'><dir id='730DFA2468'><tfoot id='730DFA2468'></tfoot><noframes id='730DFA2468'>

    • <optgroup id='730DFA2468'><strike id='730DFA2468'><sup id='730DFA2468'></sup></strike><code id='730DFA2468'></code></optgroup>
        1. <b id='730DFA2468'><label id='730DFA2468'><select id='730DFA2468'><dt id='730DFA2468'><span id='730DFA2468'></span></dt></select></label></b><u id='730DFA2468'></u>
          <i id='730DFA2468'><strike id='730DFA2468'><tt id='730DFA2468'><pre id='730DFA2468'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:hotspot    - browse:5136
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore